Dr. Reddy's Laboratories Ltd.'s rituximab, a biosimilar version of Roche's monoclonal antibody MabThera/Rituxan, has made significant inroads in markets like India and Ukraine; approvals are also in place in Venezuela and Russia - all eyes are on a Russian tender for the product anticipated in November this year.
Dr Reddy's Rituximab Build-Up And Going Beyond The Pill
Nine years after the launch of its biosimilar rituximab in India, Dr Reddy's Laboratories (DRL) claims a tenfold increase in the number of patients treated with the monoclonal antibody. M V Ramana, DRL's executive vice president and head branded markets (India and emerging countries) tells Scrip about his plans for the product in Russia and elsewhere and the firm's thrust on delivering care beyond the pill.
More from Business
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
More from Scrip
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
The company closed a $150m series C funding round shortly after opening the second part of its Phase I/II study of ATSN-201 and partnering with a Nippon Shinyaku on ATSN-101.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.